Veloxis Pharmaceuticals was granted Orphan Drug status by the FDA for Envarsus for prevention of organ rejection in patients receiving allogenic kidney transplants. Envarsus is a once-daily formulation of tacrolimus employing the company’s MeltDose technology.   Orphan drug designation is granted for potential treatments that target a patient population of 200,000 or less. For Envarsus, the designation is based on the potential that Envarsus may be clinically superior to currently marketed...